Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Alzheimer's disease, one of the most common forms of dementia, is characterized by a slow
progression of cognitive impairment and neuronal loss. Currently, approved treatments for …

Fisetin has been shown to be beneficial for brain injury and age-related brain disease via
different mechanisms. The purpose of this study was to determine the presence of senescent …

Alzheimer's disease (AD) is a highly prevalent neurodegenerative condition that has
devastating effects on individuals, often resulting in dementia. AD is primarily defined by the …

It has been four years since long COVID—the protracted consequences that survivors of
COVID-19 face—was first described. Yet, this entity continues to devastate the quality of life …

Cellular senescence is a biological aging hallmark that plays a key role in the development
of neurodegenerative diseases. Clinical trials are currently underway to evaluate the …

Background The role of senescence in disease contexts is complex, however there is
considerable evidence that depletion of senescent cells improves outcomes in a variety of …

Therapeutically targeting senescent cells seems to be an interesting perspective in treating
chronic lung diseases, which are often associated with human aging. The combination of the …

Senescent cells may have a prominent role in driving inflammation and frailty. The impact of
cellular senescence on frailty varies depending on the assessment tool used, as it is …

Senescent cells can either to promote immunosuppressive tumor microenvironment or
facilitate immune surveillance. Despite the revolutionary impact of cancer immunotherapy …